2023-04-28-上交所-黑龙江珍宝岛药业股份有限公司2022年度监事会工作报告_5页_422kb

2022 Annual Supervisory Board Work Report Summary

Overview

In 2022, the Supervisory Board of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. operated in strict compliance with laws and company regulations, focusing on ensuring the company's lawful operations, financial integrity, and protection of shareholder interests.

Key Supervision Activities

• Supervised company operations, financials, transactions, and executive conduct, confirming compliance with laws and company rules.
• Attended and reviewed all shareholder and board meetings, affirming that decisions aligned with legal and regulatory standards.
• Evaluated and approved various matters, including financial reports, fundraising, and incentive plans, with no issues found that harmed shareholders.

Membership

The board includes Lan Peibao, Li Xuedong, and Huang Jing (new employee representative), following updates due to Zhang Zhongfang's resignation.

Specific Actions and Opinions

• Conducted six meetings, reviewing agendas such as financial budgets, redemption plans, and关联交易, all deemed appropriate.
• Expressed approval for financial transparency, effective internal controls, and secure fund management, highlighting no major risks.
• Addressed regulatory reviews and company governance, noting strong adherence to norms.

Future Plans

The 2023 agenda emphasizes continued supervision, improving governance through learning and periodic reviews, with a focus on safeguarding company and shareholder interests.